A Randomized, Double-Blind, Phase 2b Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption

Trial Profile

A Randomized, Double-Blind, Phase 2b Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs AGS 004 (Primary)
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Argos Therapeutics Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Jan 2016 Status changed from active, no longer recruiting to completed according to results published in the JAIDS.
    • 08 Jan 2016 Results published in the JAIDS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top